EDMONTON, Alberta, June 12, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI) is pleased to announce that it has made a submission to the U.S. Food and Drug Administration (the “FDA”) to consider the Company’s proprietary technology as a method to reduce nicotine levels in tobacco.
On July 28, 2017, the FDA announced a new comprehensive plan that places nicotine, and the issue of addiction, at the center of the agency's tobacco regulation efforts. On March 16, 2018, the FDA issued an Advanced Notice of Proposed Rulemaking to explore a product standard to set the maximum nicotine level for cigarettes, so that cigarette products are minimally addictive or non-addictive.
Radient expects that its Microwave Assisted Processing (MAP™) method would enable nicotine to be safely extracted from tobacco as an in-line part of the cigarette manufacturing process. This would allow reduced-nicotine cigarettes to be mass-produced, while avoiding costly and complex changes to tobacco farming and blending practices or resorting to genetically modified crops. Nicotine extracted by Radient’s MAP™ could also be recovered for use in less harmful nicotine products such as e-cigarettes.
On September 20, 2017, Radient announced the results of over four years of research and development with a leading tobacco manufacturer. Results demonstrated nicotine depletion of over 95% across multiple cured tobacco types, and the potential for nicotine depletion in a continuous-flow system at industrially-relevant scales.
Denis Taschuk, President and CEO of Radient commented: “We are supportive of the FDA’s strategy to dramatically reduce smoking. On June 5th, we announced a patent application on our unique MAP™ method for selectively extracting nicotine from tobacco. We believe our process is an effective and efficient way to remove nicotine from tobacco, and we are pleased to make this submission to the FDA for consideration in their roadmap to lower nicotine levels in cigarettes.”
Radient extracts natural compounds from a range of biological materials using MAP™, a patented technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health and personal care markets. Since 2016, Radient has expanded its offerings to enter the cannabinoids market utilizing its MAP™ platform to process and extract cannabinoids including cannabidiol and tetrahydrocannabinol from cannabis biomass. Visit www.radientinc.com for more information.
Denis Taschuk, Chief Executive Officer, firstname.lastname@example.org,
Mike Cabigon, Chief Operating Officer, email@example.com,
Forward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the Company’s submission to the FDA; the Company’s ability to extract nicotine from tobacco, the results of the Company’s research and development regarding nicotine extraction and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.